Article Text

PDF
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer
  1. A Juuti1,
  2. J Louhimo1,
  3. S Nordling2,
  4. A Ristimäki2,
  5. C Haglund1
  1. 1Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland
  2. 2Department of Pathology, Helsinki University Central Hospital and University of Helsinki
  1. Correspondence to:
    Dr Caj Haglund
    Department of Surgery, Helsinki University Central Hospital, PO Box 340, 00029 HUS, Helsinki, Finland; caj.haglund{at}hus.fi

Abstract

Background: Cyclooxygenase-2 (COX-2) overexpression is related to poor outcome in several cancers. COX-2 is upregulated in 42–90% of pancreatic ductal adenocarcinomas and is a potential target for chemotherapy. Earlier studies have not shown the expression of COX-2 to be a prognostic factor in pancreatic cancer.

Objective: To evaluate the prognostic value of COX-2 in a series of patients with pancreatic adenocarcinoma.

Methods: 128 patients operated on for pancreatic adenocarcinoma at Helsinki University Central Hospital between 1974 and 1998 provided sections from primary tumours which were immunohistochemically stained with a COX-2-antihuman monoclonal antibody.

Results: Cytoplasmic COX-2 reactivity (>5%) occurred in 46 specimens (36%), correlating neither with age, sex, stage, size, tumour stage, nodal metastases, nor grade. Lack of COX-2 expression correlated with distant metastases (p = 0.026). In univariate survival analysis, COX-2 expression (p = 0.0114), stage (p = 0.0002), grade (p = 0.0001), and age (p = 0.042) had prognostic significance. One, two, and five year survival rates were 51%, 32%, and 8% in the COX-2 negative groups compared with 34%, 5%, and 5% in the COX-2 positive groups (p = 0.011). Prognostic significance was especially high for patients operated on with curative intent (p = 0.004). In multivariate analysis, COX-2 was an independent prognostic factor (hazard ratio = 1.6 (95% confidence interval, 1.1 to 2.3)).

Conclusions: Expression of COX-2 was associated with poor outcome from pancreatic ductal adenocarcinoma and was independent of tumour stage, grade, or age in multivariate analysis.

  • COX-2, cyclooxygenase-2
  • HR, hazard ratio
  • NSAID, non-steroidal anti-inflammatory drug
  • TNM, tumour stage, node, metastasis classification
  • UICC, International Union Against Cancer
  • pancreatic neoplasms
  • cyclooxygenase-2
  • survival
  • immunohistochemistry

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.